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Generic substitution in allergic rhinitis
To the Editor: We would like to clarify the paragraph on generic 
substitution (paragraph 9) in the guideline on allergic rhinitis 
published as a supplement to the SAMJ of December 2006.1
The authors of the guideline state that generic substitution 
of drugs should not be done, unless trials showing clinical 
equivalence have been undertaken.  From a regulatory 
perspective, antihistamines and intranasal corticosteroids are 
not included in the Medicines Control Council (MCC)’s list of 
non-substitutable medicines2 and this recommendation would 
therefore be incorrect.
We know of no randomised controlled clinical trials 
comparing innovator and therapeutically equivalent generic 
products in the treatment of allergic rhinitis.  The statement in 
the guideline is therefore not evidence-based or substantiated.  
In the absence of evidence the Allergy Society of South Africa 
is unable to make a recommendation either way, and it will 
therefore be up to health care professionals, health care funders 
and patients themselves to decide which product is best suited 
to the individual.  We believe that generic products that are 
therapeutically equivalent have enabled greater availability of 
more cost-effective therapy to patients with allergic rhinitis.
We would also like to point out that reference 191 should 
read ‘The Medicines and Related Substances Act, Act 101 of 
1965, as amended, Section 22F’.
Sharon Kling
Chairman, on behalf of the Allergy Society of South Africa
sk@sun.ac.za
1.  Potter PC, Carte G, Davis G, et al. Clinical Management of Allergic Rhinitis – the Allergy 
Society of South Africa Consensus Update. S Afr Med J 2006; 96(12, part 2): 1269-1272.
2.  Medicines Control Council. Generic substitution December 2003 version 1. www.mccza.com 
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Plea for privacy
To the Editor: It is surprising that the South African Medical 
Association (SAMA) has ‘called on the medical profession, 
media, political parties and the public to respect the privacy of 
the Minister of Health, and to stop speculating about her health 
and the cause of her medical condition’ (Medigram vol 15, No. 4, 
16 March 2007).
Compassion is, of course, due to all who have serious 
illness, and the seriousness of the minister’s illness makes 
this particularly the case. However, requests for privacy from 
enquiry into the cause and sequelae of her illness raise a 
different aspect.
Dr Manto Tshabalala-Msimang elected to go into public office 
and ipso facto expose herself to public scrutiny.  Further, as a 
Minister of Government she became a public servant, and the 
public has a right to know whether their employee is capable of 
fulfilling the demands of office.
 Unfortunately the Minister has shown herself to be less than 
forthright regarding her illness, and the impression is that she 
sought to cover up its cause and effects. In these circumstances 
her employers (the electorate) have valid cause to speculate 
about her illness. Speculation will be inevitable and legitimate 
until she clarifies her incapacity.
If Dr Manto Tshabalala-Msimang had wished to preserve 
her privacy, the direction open to her was to resign early in her 
illness, and allow an unimpaired replacement to take office. 
This would have allowed her to control her privacy, as well as 
enhancing the esteem in which one assumes she would want to 
be held.
J P Driver-Jowitt 
3 Norfolk Road
Newlands
Cape Town
driver-jowitt@kingsley.co.za
Collapsing focal segmental 
glomerulosclerosis as a possible 
complication of valproic acid  
To the Editor: Long-term use of valproic acid (VPA) leads to 
multiple organ damage, including tubulointerstitial nephritis.1 
Collapsing focal segmental glomerulosclerosis (CFSGS) associ-
ated with VPA has never been reported. Here we report on a 
case in which such an association appears highly probable.
In October 1995, a 35-year-old man was admitted to the 
nephrology unit (Lapeyronie Hospital, Montpellier, France) for 
oedema of the lower limbs. His history was of epilepsy since 
1989, treated with VPA, and chronic renal failure (glomerular 
filtration rate (GFR) 34.14 ml/min in April 1995). On admis-
sion, clinical examination showed blood pressure 160/110 
mmHg, weight 68.4 kg and oedema of the lower limbs. Acute 
abdominal pain occurred during hospitalisation. Laboratory 
examination showed the following findings: GFR 20.22 ml/min, 
albumin 22 g/l, and proteinuria 4.85 g/d. Other tests were 
normal, including VPA blood level and serology. Kidney biopsy 
(light microscopy) showed collapse of the glomeruli with severe 
vacuolisation of the podocytes (Fig. 1). Immunofluorescence 
study showed no immune deposits. Abdominal computed to-
mography (CT) scan revealed pancreatitis. As VPA toxicity was 
suspected, carbamazepine was substituted for VPA. Haemodi-
alysis was started in April 1996.
CFSGS related to VPA toxicity has never been reported. CF-
SGS has been related to HIV.2 In the present case chronic renal 
lesions might have evolved to CFSGS, but such a possibility has 
never been reported before.3 The causal role of VPA appears 
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to us likely. Indeed vacuoles in tubules, known to be related to 
VPA toxicity,1 were also found in the glomeruli. These vacuoles 
might have originated the collapse of the glomeruli. Further-
more VPA toxicity is related to time exposure but not to blood 
level and occurs through lipid peroxidation,4 and our patient 
had been using VPA for several years. Chronic renal failure 
could have also magnified VPA toxicity through production of 
peroxides. Acute pancreatitis occurring at the time of oedema 
suggests renal damage by VPA as pancreatitis can occur after 
VPA.5 In conclusion, long-term use of VPA could lead to CFSGS. 
Assessment of renal function in this setting must be mandatory. 
When renal dysfunction is present, preferring another antisei-
zure drug is highly advisable.
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Mosvold Hospital ARV programme
To the Editor: Mosvold Hospital is a 250-bed government 
district hospital in northern KwaZulu-Natal. It has a catchment 
area of 110 000. The HIV-positivity rate for the area, as 
determined by prevention of mother-to-child transmission 
(PMTCT) statistics, is 28%.
The antiretroviral (ARV) programme at Mosvold Hospital 
began on 16 September 2004. By 7 December the first 100 
patients had commenced treatment and by 30 October 2006,  
1 400 had been started on ARVs.
The programme has gone through many changes. It started 
as a hospital-based programme, but after 3 months it was 
changed to a decentralised, clinic-based programme. A new 
ARV prescription card was developed allowing easy follow-up 
of patients, results and side-effects. Initially we only allowed 
a certain number of patients to start each month, but this was 
changed to a ‘no waiting list’ policy after a few months. A 
HAST committee was developed and continues to meet on a 
monthly basis, a new database was developed, and an ARV 
policy manual was developed and distributed to clinics.
Of the first 100 patients started on ARVs, 89 are still on 
the programme and in the district. Of those who left the 
programme, 8 died, 1 defaulted medication, and 2 transferred 
out of the district to return to work.
Of the 8 patients who died, 5 were identified as at high risk at 
the time of commencing medication according to one or more 
of the following criteria: (i) CD4 count < 50 cells/ul; (ii) World 
Health Organization stage 4 disease; (iii) new opportunistic 
infection in the month before starting ARVs; (iv) haemoglobin 
level < 8 g/dl; and (v) on intensive-phase tuberculosis 
treatment.
Of the 3 lower-risk patients, 1 died as a result of suicide, 1 
as a result of clinically diagnosed lactic acidosis (at that time 
we were unable to measure lactate levels), and 1 as a result of 
immune reconstitution syndrome.
Of the remaining 89 patients, 76/89 (85%) have viral loads < 
400 on their 18 - 24-month blood work; 5/89 (5.6%) have viral 
loads 400 - 5 000 (3 of these are children who are thriving); 5/89 
(5.6%) have levels that would allow them to be considered for 
regimen 2; (one has changed and is doing well; the others have 
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Fig. 1. Renal biopsy Masson trichrome x 400: collapsing focal and 
segmental glomerulosclerosis. Note the collapse of the glomerular tuft (1) 
and the intense vacuolisation of the podocytes (2).
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